Clinical Cancer Research Molecular Diagnostics in Cancer Therapeutic Development: Fulfilling the Promise of Personalized Medicine Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cui, N.
Right arrow Articles by Shibahala, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cui, N.
Right arrow Articles by Shibahala, T.
Clinical Cancer Research Vol. 11, 2713-2719, April 2005
© 2005 American Association for Cancer Research


Cancer Therapy: Preclinical

Effect of YM529 on a Model of Mandibular Invasion by Oral Squamous Cell Carcinoma in Mice

Nianhui Cui1, Takeshi Nomura2, Hiroyasu Noma2, Keiko Yokoo2, Ryo Takagi2, Sadamitsu Hashimoto3, Masato Okamoto4, Mitsunobu Sato4, Guangyan Yu1, Chuanbin Guo1 and Takahiko Shibahala2

Authors' Affiliations: 1 The First Department of Oral and Maxillofacial Surgery, Stomatology School, Peking University, Beijing, China; 2 First Department of Oral and Maxillofacial Surgery, 3 Department of Pathology, Tokyo Dental College, Chiba; and 4 Second Department of Oral and Maxillofacial Surgery, Tokushima University, Tokushima, Japan

Requests for reprints: Takeshi Nomura, The First Department of Oral and Maxillofacial Surgery, Tokyo Dental College, 1-2-2 Masago, Mihama-Ku, Chiba City 261-8502, Japan. Phone: 81-43-270-3973; Fax: 81-43-270-3975; E-mail: tanomura{at}tdc.ac.jp.

Purpose: This study examined the mechanisms of osteoclast-mediated bone invasion in a model of oral squamous cell carcinoma (OSCC). C3H/HeN mice were inoculated with SCC VII cells into the masseter region to establish an animal model of mandibular invasion by OSCC.

Experimental Design: The mice were divided into three groups: a control group, given daily s.c. injections of saline; group 1, given 2 µg per mouse per day of the bisphosphonate YM529; and group 2, given 10 µg per mouse per day of YM529. After 3 weeks of treatment, the lesions were studied by micro-computed tomography. After tartrate-resistant acid phosphatase (TRAP) staining, the osteoclasts were easily identified, and the percentages of the area occupied by osteoclasts were calculated by computer for each sample. The tumors were analyzed by RT-PCR to determine the mRNA expression of interleukin-6 (IL-6), parathyroid hormone–related protein (PTHrP), tumor necrosis factor-{alpha} (TNF-{alpha}), receptor activator of nuclear factor-{kappa}B (RANK), RANK ligand (RANKL), and osteoprotegerin.

Results: SCC VII cells rapidly multiplied in the masseter muscle of the mice. Bone invasion was evident only in the control group on micro-computed tomography. On TRAP-stained slices, the percentages of osteoclasts in groups 1 and 2 were significantly lower than that in the control group. The mRNA expressions of IL-6, PTHrP, THF-{alpha}, and RANK decreased as the concentration of YM529 increased.

Conclusions: We conclude that various cancer-derived cytokines play important roles in the invasion of bone by OSCC. YM529, a third-generation bisphosphonate, can suppress osteoclast-mediated bone invasion by OSCC. The mechanism of this effect might involve inhibition of cytokines such as IL-6, PTHrP, TNF-{alpha}, and RANK by YM529.

Key Words: oral cancer • bone invasion • bisphosphonate




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
K. Inoue, T. Karashima, S. Fukata, A. Nomura, C. Kawada, A. Kurabayashi, M. Furihata, Y. Ohtsuki, and T. Shuin
Effect of Combination Therapy with a Novel Bisphosphonate, Minodronate (YM529), and Docetaxel on a Model of Bone Metastasis by Human Transitional Cell Carcinoma
Clin. Cancer Res., September 15, 2005; 11(18): 6669 - 6677.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.